{"disease":{"id":"relapsed-or-refractory-neuroblastoma","name":"relapsed or refractory neuroblastoma"},"drugs":{"marketed":[{"drug_id":"naxitamab","indication_name":"Relapsed or Refractory High-Risk Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hu3F8","generic_name":"NAXITAMAB","company_name":"Y-Mabs Therapeutics Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Glycolipid Disialoganglioside-directed Antibody [EPC]","quality_score":53,"revenue":null,"mechanism":"Hu3F8 works by binding to a specific glycolipid on cancer cells, marking them for destruction by the immune system."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07444918","title":"Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT02761915","title":"A Phase I Trial of Anti-GD2 T-cells (1RG-CART)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Cancer Research UK","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}